18F-FDG PET/CT for predicting outcomes of diffuse large B-cell lymphoma：shall it be performed in the interim versus later phase of chemotherapy?
LI Huizhi
WU Hubing
WANG Quanshi
LI Hongsheng
ZHOU Wenlan
TIAN Ying
DONG Ye
Abstract：Objective To compare the value of 18F-FDG PET/CT performed in the interim and later phase of chemotherapy in predicting the prognosis of diffuse large B-cell lymphoma (DLBCL). Methods 18F-FDG PET/CT was performed in 71 patients with DLBCL in the interim phase of chemotherapy (3-4 cycles) and in another 71 patients in the later phase of chemotherapy (5-8 cycles). The patients were followed up for an average of 28.73 months (18-114 months) to compare the progression-free survival (PFS) and the PFS rate. Results The positive finding rate was similar between 18F-FDG PET/CT performed in the interim and the later phase (36.6%vs 33.8%,χ2=12.423, P>0.05). The PFS was much longer in patients with negative findings than in those with positive findings in both the interim (63.56 vs 19.23 months, P=0.000) and later phase groups (65.78 vs 24.32 months, P=0.000), but showed no significant difference between the negative patients (P>0.05) or between the positive patients (P>0.05) in the two groups. The PFS rate was significantly greater in patients with negative than those with positive findings in the interim group (73.3%vs 15.4%, P=0.000) and in the later phase group (74.5%vs 16.7%, P=0.000), but comparable between the negative (P>0.05) and between the positive patients (P>0.05) in the two groups. Conclusions 18F-FDG PET/CT in the interim and later phase of chemotherapy has similar value for predicting the prognosis of DLBCL, and we therefore recommend that 18F-FDG PET/CT be performed in the interim but not in the later phase.
Keywords：diffuse large B-cell lymphomachemotherapyemission-computed tomographyX-ray computedprognosis prediction
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 208-212 )